Adcetris is also indicated as monotherapy or in combination with chemotherapy for the treatment of certain types of classical Hodgkin lymphoma, anaplastic large cell lymphoma and peripheral T-cell ...

This marks the eighth FDA-approved indication for ADCETRIS, solidifying its role in the treatment of lymphomas. According to InvestingPro analysis, Pfizer's stock is currently trading near its 52 ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green light to treat large B-cell lymphoma (LBCL). The CD30-directed antibody ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ineligible for autologous stem cell transplantation. The FDA has approved ...

NICE has ruled that Takeda’s Hodgkin’s lymphoma treatment Adcetris should no longer be funded on the NHS, saying there isn’t enough evidence to support its use. The treatment is a ‘legacy ...

Replacing transplant and chemo with CI-based therapy and ISRT maintains survival, reduces side effects in younger patients ...

Adcetris has a list price of £2,500 per 50 mg vial – equivalent to almost £48,000 for the six treatment cycles required by the average patient – but has been recommended by NICE after Takeda ...

FDA Approves Expanded Use of Pfizer’s Cancer Drug Adcetris The FDA approved Pfizer’s cancer drug Adcetris for its eighth indication, a type of lymphoma. The FDA approval is for Adcetris in ...

Approval is based on positive data from the Phase 3 ECHELON-3 trial, which demonstrated ADCETRIS regimen reduced the risk of death by 37%, a statistically significant, clinically meaningful ...

(RTTNews) - Pfizer Inc. (PFE) Wednesday announced the FDA approval of its supplemental Biologics License Application or sBLA for ADCETRIS otherwise known as brentuximab vedotin combined with ...